



Tool for reducing uncertainties in the evidence generation  
for specialised treatments for rare diseases

In 2017 the **multi-stakeholder initiative** was set up to:

**Facilitate a shared understanding of the challenges faced by manufacturers, regulators, HTA, Payers and patient groups in the development and use of real world evidence to address uncertainties for these technologies**

The initiative builds on work already undertaken by:

**Outcomes based pricing and reimbursement of innovative medicines**

**The use of real world data throughout an innovative medicine's lifecycle**



INAMI-RIZIV

POSITION STATEMENT

Open Access



**Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)**

Lieven Annemans<sup>1</sup>, Ségolène Aymé<sup>2</sup>, Yann Le Cam<sup>3</sup>, Karen Facey<sup>4</sup>, Penilla Gunther<sup>5</sup>, Elena Nicod<sup>6</sup>, Michele Reni<sup>7</sup>, Jean-Louis Roux<sup>8</sup>, Michael Schlander<sup>9,10,11</sup>, David Taylor<sup>12</sup>, Carlo Tomino<sup>13</sup>, Josep Torrent-Farnell<sup>14</sup>, Sheela Upadhyaya<sup>15</sup>, Adam Hutchings<sup>16</sup> and Lugdwine Le Dez<sup>17</sup>

ORPH-VAL

# Multi-stakeholder participation

## STAKEHOLDERS



Prof. Lieven Annemans  
University of Ghent



Dr Karen Facey  
University of Edinburgh



Jo De Cock  
CEO – INAMI



John Bowis  
FIPRA (Chair)



Yann Le Cam  
CEO – EURORDIS



European  
Reference  
Networks



Zorginstituut Nederland



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**NICE** National Institute for  
Health and Care Excellence



FEDERAL MINISTRY OF LABOUR,  
SOCIAL AFFAIRS, HEALTH AND  
CONSUMER PROTECTION



INAMI-RIZIV

**HAS**

HAUTE AUTORITÉ DE SANTÉ



eunetha  
EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT



*The future of cancer therapy*



European Confederation of  
Pharmaceutical Entrepreneurs AISBL



The European Association for Biomedicine



RARE DISEASES EUROPE

**BIOMARIN**



**OBSERVER**



## The approach

To provide a **mutual understanding of the challenges and trade-offs** in evidence development for highly specialised technologies

## The rationale

Approaches that are agreed upon through a multi-stakeholder dialogue has the potential to **increase trust and uptake** of such evidence in health care decision-making

# Development of Consensus Paper providing a technical but pragmatic methodology



a **taxonomy of uncertainties** relating to these challenges to delineate their nature and role in HTA and Payer decision-making.

**guidance** to decision-makers on real-world evidence generation options to address these uncertainties and to support understanding of their scientific validity.

# The Paper



**Addressing uncertainties in the evidence generation for highly specialised treatments in complex or rare conditions**

Lead author: Professor Lieven Annemans  
(Professor of Health Economics, University of Ghent)

Co-author: Dr Karen Facey, HTAi



## **TRUST4RD building blocks:**

- 1.** Typology of uncertainties – related to the **disease, medicine or health ecosystem**
- 2.** Qualitative assessment of **importance/impact** of a given uncertainty
- 3.** Overview of available **data sources**
- 4.** List of issues related to different **data sources**
- 5.** Permanent communication line between industry and HTA bodies/payers

# Assessing the impact and importance of uncertainties

Therapy	Disease	Health Ecosystem
<ul style="list-style-type: none"><li>▪ Magnitude of treatment effect</li><li>▪ Possibility of waning effect</li><li>▪ Impact of biomarker on treatment effect</li><li>▪ Dose required for optimal effect</li><li>▪ Relevance of treatment effect to patients</li><li>▪ Impact on quality of life</li><li>▪ Impact on society and caregivers</li><li>▪ Adverse events and safety</li><li>▪ Which patients treatment works best</li></ul>	<ul style="list-style-type: none"><li>▪ Natural history of the disease</li><li>▪ Relationship between surrogate and hard endpoints (e.g. long-term survival)</li><li>▪ Extent of unmet need (impact of disease on quality of life and survival)</li><li>▪ Incidence and prevalence of the disease</li></ul>	<ul style="list-style-type: none"><li>▪ Current pathway and standard of care</li><li>▪ Patient acceptability and compliance (not therapy related)</li><li>▪ Provider prescription patterns</li><li>▪ Consequences to healthcare system (e.g. extra costs)</li><li>▪ Consequences to society (e.g. reduced absenteeism)</li></ul>

**Some uncertainties may have a larger impact on relative effectiveness and value for money than others**

# Data sources

Experimental  
evidence about  
current  
management

Experimental  
evidence about  
new medicine

Real World Evidence  
about current  
management

Real World Evidence  
about new medicine

*4 types of data sources can address uncertainties*




# The way forward...

## List of issues

Issues will occur with the available data sources. It is important that these issues are explicitly listed and discussed, leading to suggested solutions

## A permanent communication line



A dialogue can lead to solutions, using the building blocks of the tool

# Process and deliverables: overview

